P. Benedetti, L. Pierelli, G. Scambia, M. L. Foddai, M. G. Salerno, G. Menichella, M. Vittori, F. Maneschi, U. Caracussi, R. Serafini, G. Leone and S. Mancuso, “HighDose Carboplatin, Etoposide and Melphalan (CEM) with Peripheral Blood Progenitor Cell Support as Late Intensification for High-Risk Cancer: Non-Haematological, Haematological Toxicities and Role of Growth Factor Administration,” British Journal of Cancer, Vol. 75, No. 8, 1997, pp. 1205-1212. doi:10.1038/bjc.1997.206

has been cited by the following article:

• TITLE: Darbepoietin-Alfa after High-Dose Melphalan and Autologous Hemopoietic Progenitor Cell in Multiple Myeloma Patients: A Pilot Study

  AUTHORS: Massimo Martino, Ida Callea, Tiziana Moscato, Antonella Pontari, Elisa Spiniello, Roberta Fedele

  KEYWORDS: Darbepoietin-Alfa; Anemia; Multiple Myeloma; Autologous Hematopoietic Progenitor Cell Transplanta-tion

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.2 No.3, September 4, 2012

  ABSTRACT: We describe the effects of Darbepoietin-alfa (Darbe) administration in Multiple Myeloma (MM) after autologous he-mopoietic progenitor cell transplantation (AHPCT). 26 MM patients undergoing AHPCT entered this study. 34 hemo-globin (Hb)-matched patients who had not received recombinant human erythropoietin (Epo) or Darbe and were treated with the same protocol were retrospectively selected for comparative data. Darbe (150 micro g total dose/weekly) was initiating in four weeks after AHPCT, with the aim of achieving an Hb level of ≥11 g/dl. The time to response to Darbe therapy was longer in the patients with Hb